XML 34 R23.htm IDEA: XBRL DOCUMENT v3.5.0.1
Agreements With, and Other Related Party Transactions: (Details)
12 Months Ended
Feb. 29, 2016
USD ($)
item
Feb. 28, 2015
USD ($)
Agreements with, and other related party transactions    
Capital contributed | $ $ 252,039 $ 355,729
Clinical trial costs paid direct | $ $ 1,790,386 2,548,598
License Agreement | United States    
Agreements with, and other related party transactions    
Number of patents issued on which exclusive rights are owned 8  
Number of Initial Patents 5  
License Agreement | Canada    
Agreements with, and other related party transactions    
Number of patents issued on which exclusive rights are owned 4  
License Agreement | Mexico    
Agreements with, and other related party transactions    
Number of patents issued on which exclusive rights are owned 1  
Dr. Burzynski    
Agreements with, and other related party transactions    
Capital contributed | $ $ 252,039 355,729
Clinical trial costs paid direct | $ $ 1,790,386 $ 2,548,598
Dr. Burzynski | License Agreement    
Agreements with, and other related party transactions    
Number of other countries in which Patent Offices and Patent Officers issued patents 34  
Dr. Burzynski | Research Funding Agreement    
Agreements with, and other related party transactions    
Number of parties 2  
Renewable term 1 year  
Dr. Burzynski | Research Funding Agreement | Minimum    
Agreements with, and other related party transactions    
Notice period for nonrenewal prior to expiration of term of agreement 30 days  
Dr. Burzynski | Research Funding Agreement | Maximum    
Agreements with, and other related party transactions    
Net proceeds of any stock offering or private placement | $ $ 1,000,000  
Ownership percentage for termination of agreement 0.50%  
Dr. Burzynski | Royalty Agreement    
Agreements with, and other related party transactions    
Royalty interest as a percentage of gross income 10.00%  
Number of patients to be treated with antineoplaston products in option two, percentage added to cost of production to determine overall price 10.00%  
Dr. Burzynski | Royalty Agreement | Maximum    
Agreements with, and other related party transactions    
Number of patients to be treated with antineoplaston products under the option in which related party would have the right to produce the products without paying any fees 1,000  
Number of patients to be treated with antineoplaston products under the option in which related party would have the right to purchase the products from the company at specified price 1,000